MOTS-c: the mitochondrial-derived peptide in the exercise-mimetic conversation

MOTS-c is a 16-amino-acid mitochondrial-derived peptide encoded within the MT-RNR1 (12S rRNA) gene of the mitochondrial genome. it was reported in 2015 and expanded the long-standing view that mitochondria only output respiratory-chain proteins. it acts as a stress-responsive signaling peptide that converges on AMPK, the same energy-sensing kinase activated by exercise, and is currently the lead mechanistic candidate in the exercise-mimetic peptide conversation.

what is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. it is a 16-residue peptide whose coding sequence sits inside the mitochondrial-DNA-encoded 12S ribosomal RNA gene, MT-RNR1. that location was scientifically important because it shifted the picture of mitochondrial output from classic oxidative-phosphorylation proteins toward bioactive peptide signaling.

MOTS-c was reported by Lee and colleagues in Cell Metabolism in 2015 as a short mitochondrial-derived peptide (MDP) with metabolic activity in mice [1]. it belongs to a small family of MDPs that includes humanin and the SHLPs, all of which appear to be released under metabolic stress and act as systemic signals rather than as components of the respiratory chain. a useful framing for beginners is that mitochondria do not only run the engine, they also send messages, and MOTS-c is one of those messages.

the 16-amino-acid size puts MOTS-c in the small-peptide range. small size has practical implications for pharmacology, including challenging plasma stability and active-transport requirements, and it is part of why mature drug-development programs around MOTS-c are still early. there is no FDA-approved MOTS-c drug. supply that exists in the peptide-research market is unaudited and operates outside the FDA-approved drug system.

how does it work?

MOTS-c perturbs one-carbon and purine-linked metabolism, raises AICAR-related signaling, and converges on AMPK activation. AMPK is the same energy-sensing axis activated by aerobic exercise, which is the reason MOTS-c enters the exercise-mimetic conversation at the mechanism level. under stress, MOTS-c can also translocate to the nucleus and modulate transcription, which is unusual for a mitochondrial-encoded peptide.

the cleanest mechanistic arc from the foundational studies runs through three nodes. first, MOTS-c shifts one-carbon and purine-linked metabolism in ways that increase AICAR-related signaling. AICAR is a long-recognized chemical AMPK activator, so the rise in AICAR-related signal is the proximal explanation for AMPK activation. second, AMPK activation engages the same downstream metabolic programs that exercise activates, including glucose uptake, fatty-acid oxidation, and mitochondrial-biogenesis-supporting transcription factors [1].

the third node was reported by Kim and colleagues in Cell Metabolism in 2018: under metabolic stress, MOTS-c can translocate from the mitochondria to the nucleus and regulate nuclear gene expression, including antioxidant and stress-response genes [2]. this mitonuclear translocation is unusual for a mitochondrial-encoded peptide and is the reason MOTS-c is often described as a stress-responsive transcriptional regulator rather than only a metabolic enzyme modulator. Reynolds and colleagues in Nature Communications in 2021 extended the picture to whole-animal exercise biology: in mice, MOTS-c improved exercise-related physical capacity across age strata, and exercise itself raised endogenous MOTS-c in human skeletal muscle and circulation [3]. that is the strongest single basis for the exercise-mimetic framing.

what does the evidence show?

the MOTS-c evidence base is strongest at the mechanism and rodent-physiology level, moderate at the human-biology level (genetic and biomarker associations), and weak at the human-therapeutic-efficacy level. there is no advanced interventional efficacy program with MOTS-c as the administered drug in the public clinical-trials registry as of early 2026.

on the genetics side, the m.1382A>C mitochondrial variant, which produces the K14Q substitution in MOTS-c, has been associated with higher type 2 diabetes susceptibility in East Asian male cohorts, with an interaction with lower physical activity [4]. that finding supports the biologic relevance of MOTS-c signaling in humans, but it is not the same as showing that exogenous MOTS-c is a therapy.

on the biomarker side, circulating MOTS-c does not always move in the same direction across human cohorts. some older cardiometabolic datasets reported lower circulating MOTS-c in dysfunction contexts. Yoon and colleagues in 2026 reported higher MOTS-c in adults with obesity and interpreted it as possible compensatory stress-response signaling [5], and Cao and colleagues in 2025 reported higher MOTS-c in acute coronary syndrome with prognostic value for major cardiac events [6]. the honest framing is that circulating MOTS-c is likely state-dependent and assay-sensitive, useful for biomarker research but insufficient to anchor therapeutic claims.

on the trial-pipeline side, public registry queries return studies where MOTS-c is measured as a biomarker rather than administered as a drug. there is no Phase 3 efficacy program and no FDA-approved label match. for an honest learner, the right framing is that MOTS-c is a high-credibility mechanistic candidate in a research frontier, not a finished therapy.

regulatory and anti-doping status

MOTS-c is not FDA approved for any indication. it appears in the FDA's Category 2 bulk-substances safety-risk context for compounding evaluation, alongside other unapproved peptides like AOD-9604. it is on the World Anti-Doping Agency 2026 Prohibited List under category S4.5.2 (metabolic modulators and AMPK activators) at all times, both in and out of competition.

the FDA regulatory picture is straightforward. an openFDA drug-label search returns no MOTS-c approval, and the FDA's human drug compounding policy materials include MOTS-c in the Category 2 context, meaning the agency has flagged it as a substance for which significant safety information remains undefined. Category 2 placement is not an approval pathway and should not be presented as one.

the anti-doping picture is also clear-cut. the WADA 2026 Prohibited List places MOTS-c under S4.5.2, the metabolic modulators and AMPK activators sub-category. substances under S4 are banned in and out of competition. for any athlete in a WADA-tested sport, this is the most actionable single fact on this page: use creates direct anti-doping risk independent of the clinical-efficacy uncertainty.

safety profile and what is unknown

long-term controlled human safety data for exogenous MOTS-c do not exist. mechanistic plausibility and biomarker shifts do not replace chronic safety characterization, and that gap is itself a teaching point. responsible framing for any beginner is that the absence of reported adverse events is not the same as a clean long-term safety record.

across the broader exercise-mimetic peptide set, the bottleneck is long-term controlled safety data. for MOTS-c specifically, the published human work is dominated by biomarker measurement and genetic-association studies, both of which generate physiology data but not pharmacovigilance data. no chronic-exposure human dataset has been published, and supply quality outside of academic research settings is unaudited.

a second underrated point is that "circulating MOTS-c rises with exercise" does not automatically mean "injecting MOTS-c reproduces exercise." exercise is multi-system: neuromuscular load, cardiovascular hemodynamics, bone and tendon mechanotransduction, endothelial shear stress, autonomic balance, and immune and myokine remodeling. a single peptide can emulate a subset of metabolic signaling, but none currently reproduces the full systems-level training adaptation. the responsible educational frame is "pathway-mimetic" or "exercise-responsive peptide biology," not "exercise replacement."

where it fits in peptide biology

MOTS-c sits in the mitochondrial-derived peptide family alongside humanin and the SHLPs and in the broader exercise-mimetic conversation alongside apelin, irisin, and the historically promoted AOD-9604. it is the lead mechanistic candidate in this set, but it shares with all of them a translational gap between mechanism and validated outcomes.

the closest comparators in MDP biology are humanin and the SHLPs. Gidlund and colleagues showed that resistance training raises skeletal-muscle humanin in men with impaired glucose metabolism, and Woodhead and colleagues reported that high-intensity interval exercise raises humanin in both plasma and muscle [7]. humanin and SHLPs are therefore better framed as exercise-responsive mitochondrial peptides than as validated pharmacologic exercise mimetics, and the same is currently true of MOTS-c.

outside the MDP family, the best human exercise-mimetic signal comes from apelin, which has a small randomized phase-1 crossover study supporting improved insulin sensitivity during clamp testing in overweight men, and irisin, which is rigorously detectable in human plasma by tandem mass spectrometry but has no mature therapeutic program. AOD-9604, by contrast, is older preclinical work mostly in rodents and should not be presented as a clinically validated exercise mimic. for adjacent metabolic biology covered in our free track, the GH axis story sits in tesamorelin and the GLP-1 axis sits in semaglutide and tirzepatide; the broader pathway tour is in our free peptides and your body module.